Hansa is deploying Cradle’s end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease. LUND, Sweden and AMSTERDAM, The Netherlands, October 1, 2026 – Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and […]
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress experimentally London, UK – 1 October 2026 – DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform. […]
We need to talk about AI. Not its potential to revolutionise drug discovery, or the workplace, or even how it might threaten humanity. We need to talk about something more mundane – but still important. We need to talk about how to get AI to notice you. Because if AI is not noticing your firm, […]
Sofinnova combines its sector expertise with AWS’s AI and cloud services to help life sciences companies scale faster The collaboration expands Sofinnova’s proprietary AI platform, Sofia, including a new founder-facing version PARIS, France – June 10, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, […]
Dalton is a drug discovery platform integrating agentic AI, human expertise, and experimental data, into one continuous learning engine Announces collaboration with Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), as a client London, UK – 4 June 2026 – DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and […]
